Preop Lab Values May ID Risk of Postarthroplasty Joint Infection in Morbid Obesity
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
THURSDAY, July 25, 2024 -- Certain preoperative laboratory values may predict risk of periprosthetic joint infection (PJI) among individuals with morbid obesity undergoing arthroplasty, according to a study published in the July 17 issue of the Journal of Bone & Joint Surgery.
Sagar Telang, from the University of Southern California in Los Angeles, and colleagues sought to identify preoperative laboratory values that may serve as predictors of PJI in patients with morbid obesity undergoing total hip arthroplasty or total knee arthroplasty (TKA). Analysis included 6,780 patients (TKA: 76.7 percent) of whom 47 (0.69 percent) developed PJI within 90 days after surgery.
The researchers found that the rate of PJI was 1.69 percent for patients with a hemoglobin level of <12 g/dL (for females) or <13 g/dL (for males), 2.14 percent for those with a platelet count of <142,000/µL or >417,000/µL, 1.11 percent for those with a neutrophil-lymphocyte ratio (NLR) of >3.31, 1.69 percent for those with a platelet-lymphocyte ratio (PLR) of >182.3, and 1.05 percent for those with a systemic immune-inflammation index (SII) of >776.2. In adjusted analysis, there were significant associations between PJI and an abnormal preoperative NLR (adjusted odds ratio [aOR], 2.38), PLR (aOR, 4.86), SII (aOR, 2.44), platelet count (aOR, 3.50), and hemoglobin level (aOR, 2.62).
"These findings may help surgeons risk-stratify this high-risk patient population," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-07-26 01:15
Read more
- Wearables Linked to Higher Specific, Informal Health Care Use in A-Fib
- 20+ Sustainable Alternatives to Everyday Lifestyle Staples
- SGLT-2 Inhibitors May Cut Dementia Risk in Patients With Diabetes
- What You Need to Know About Retinol and Other Retinoids
- Bipolar Disorder in Women: Know the Facts
- Automated Multiorgan CT Can Predict Diabetes, Other Conditions
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions